Systemic Sclerosis Serum

About Systemic Sclerosis Serum

Systemic Sclerosis Serum for Autoimmune Fibrosis Research

Sanguine’s Systemic Sclerosis Serum is collected from IRB-consented adult donors with a clinically confirmed diagnosis of systemic sclerosis (SSc) and processed under standardised SOPs to preserve circulating proteins, autoantibodies and metabolites. Serum is an acellular matrix, so these samples are intended for analyte-level work — autoantibody serology, cytokine and growth-factor measurement, and proteomic or metabolomic profiling.

Autoimmunity, Vasculopathy and Fibrosis in Systemic Sclerosis

Systemic sclerosis is an autoimmune connective tissue disease in which immune activation, microvascular injury and excessive extracellular matrix deposition converge to produce skin and internal organ fibrosis. Its serology is unusually informative: SSc-specific autoantibodies are largely mutually exclusive and each tracks with a distinct clinical phenotype, which makes serum one of the most directly useful matrices in the disease.

• Anti-centromere antibodies (ACA), anti-topoisomerase I (anti-Scl-70) and anti-RNA polymerase III are the best-established SSc-specific autoantibodies and are measurable directly in serum.
• Autoantibody subset supports organ-risk stratification — ACA is associated with limited cutaneous disease and pulmonary arterial hypertension, anti-topoisomerase I with diffuse disease and interstitial lung disease, and anti-RNA polymerase III with rapidly progressive skin thickening and scleroderma renal crisis.
• Profibrotic mediators including TGF-beta pathway components, connective tissue growth factor (CTGF/CCN2) and IL-6 circulate in SSc and are accessible to immunoassay and multiplex panels.
• Vasculopathy is a defining feature rather than a complication; endothelial activation markers, angiogenic and anti-angiogenic factors are of particular interest in serum.
• Collagen and matrix turnover fragments provide candidate readouts of fibrotic activity independent of skin scoring.
• Serum avoids the anticoagulant additives present in plasma, which matters for some autoantibody assays, complement work and mass-spectrometry workflows.

Donor Stratification Available

• Cutaneous subset: limited cutaneous SSc vs diffuse cutaneous SSc
• Autoantibody status where documented (ACA, anti-topoisomerase I, anti-RNA polymerase III)
• Interstitial lung disease involvement
• Pulmonary arterial hypertension
• Raynaud phenomenon, digital ulceration or telangiectasia
• Treatment status: immunosuppressant, antifibrotic, vasodilator therapy, or treatment-naive
• Disease duration and modified Rodnan skin score where documented
• Matched healthy controls available

Product Features

• Research Use Only (RUO) human serum from clinically confirmed systemic sclerosis donors
• Processed under standardised SOPs and frozen to preserve labile analytes
• Rigorous donor screening and lot-level quality checks
• Standard and custom aliquot volumes; volumes reported per lot
• IRB-approved collection protocols with documented informed consent

De-identified Donor Data

• Physician-confirmed systemic sclerosis diagnosis and diagnosis method
• Demographics: age, sex assigned at birth, race/ethnicity
• Disease subset, duration and severity/stage where documented
• Donor-reported medications, allergies and comorbidities
• Optional laboratory values and clinical history on request

Applications

• SSc-specific autoantibody detection, titration and assay development
• Profibrotic cytokine and growth-factor profiling
• Serum proteomics and metabolomics in fibrotic disease
• Endothelial activation and angiogenesis analyte measurement
• Collagen and matrix turnover biomarker discovery and validation
• Antibody-phenotype correlation studies for organ-involvement risk
• Pharmacodynamic and treatment-response biomarker research
• Control and comparator material for autoimmune serology panels

Other Systemic Sclerosis Specimen Types

• Systemic Sclerosis Plasma
• Systemic Sclerosis Whole Blood
• Systemic Sclerosis PBMC
• Systemic Sclerosis Leukopak
• Systemic Sclerosis Skin Punch Biopsy
• Limited Cutaneous Systemic Sclerosis Serum
• Diffuse Cutaneous Systemic Sclerosis Serum

Compliance and Quality Assurance

• IRB-approved collection protocols and HIPAA-compliant data handling
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Standardised collection and processing SOPs
• Documentation support available for regulatory review

Ordering & Customization

Systemic Sclerosis Serum is available in standard and custom volumes to meet your study design. For pricing, current availability, international shipments or country-specific documentation requirements, contact learnmore@sanguinebio.com. To browse disease-state options and live stock status across our full serum inventory, visit our human serum page.